Per Norlén, Evaxion Biotech CEO
Evaxion teases 67% response rate in PhI metastatic melanoma trial
Evaxion Biotech said eight of 12 patients with metastatic melanoma who received a combination of the lead candidate and an unnamed checkpoint inhibitor had a positive response in a Phase I trial, in a sneak peak of clinical data set to be presented at ASCO next week.
The Danish biotech is developing EVX-01, a personalized cancer immunotherapy that builds off its AI platform, which identifies neoantigens for each patient.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters